3,4-Methylenedioxy-N-propylamphetamine
 | |
| Clinical data | |
|---|---|
| Other names | 3,4-Methylenedioxy-N-propylamphetamine; MDPR; N-Propyl-MDA |
| Routes of administration | Oral[1] |
| Drug class | Psychoactive drug[1] |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.217.125 |
| Chemical and physical data | |
| Formula | C13H19NO2 |
| Molar mass | 221.300 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
MDPR, also known as 3,4-methylenedioxy-N-propylamphetamine or as N-propyl-MDA, is a lesser-known psychoactive drug and a substituted amphetamine.[1][2]
Use and effects
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists MDPR's minimum dose as 200 mg orally and its duration as unknown.[1][2] MDPR is described as a "promoter"; by itself it has almost no effects on the mind, but it promotes the effects of hallucinogens, similarly to the closely related MDPH.[1] Shulgin reported that 160 mg of MDPR strongly enhanced the effects of a small (60 μg) dose of LSD,[1] and that similar enhancement of hallucinogenic effect was noted when mixing MDPR with other drugs such as psilocybin, mescaline, 2C-B, and 2C-T-7.[1] The reason for this synergistic action of MDPR has not been elucidated.[1]
Chemistry
Synthesis
The chemical synthesis of MDPR has been described.[1]
See also
References
- ^ a b c d e f g h i j Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628. MDPR entry
- ^ a b Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN 978-0-12-433951-4. Archived from the original on 13 July 2025.